152 related articles for article (PubMed ID: 32248069)
1. Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab.
Watanabe Y; Yamaguchi Y; Takamura N; Takahashi Y; Aihara M
Eur J Cancer; 2020 May; 131():1-4. PubMed ID: 32248069
[No Abstract] [Full Text] [Related]
2. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
3. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
Dasanu CA
J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
[TBL] [Abstract][Full Text] [Related]
4. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
5. Nivolumab-induced Stevens-Johnson syndrome: Not only due to PD-1 inhibition.
Rodríguez-Otero N; Chamorro-Pérez J; Fernández-Lozano C; Elías-Sáenz I; Berná-Rico E; de Nicolás-Ruanes B; Meléndez-Gispert MR; Moreno-García Del Real C; Martínez-Botas J; Cortés-Salgado A; Solano-Solares E
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2936-2938.e1. PubMed ID: 37308058
[No Abstract] [Full Text] [Related]
6. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
7. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
8. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
9. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
[No Abstract] [Full Text] [Related]
10. Reciprocal contribution of Th17 and regulatory T cells in severe drug allergy.
Hashizume H; Fujiyama T; Tokura Y
J Dermatol Sci; 2016 Feb; 81(2):131-4. PubMed ID: 26596217
[No Abstract] [Full Text] [Related]
11. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
[No Abstract] [Full Text] [Related]
12. Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.
Tadokoro T; Keshino E; Makiyama A; Sasaguri T; Ohshima K; Katano H; Mohri M
Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27650418
[No Abstract] [Full Text] [Related]
13. Nivolumab-induced aplastic anemia: A case report and literature review.
Comito RR; Badu LA; Forcello N
J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
[TBL] [Abstract][Full Text] [Related]
14. Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.
Parakh S; Cebon J; Klein O
Oncologist; 2018 Jul; 23(7):849-851. PubMed ID: 29666298
[TBL] [Abstract][Full Text] [Related]
15. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
[No Abstract] [Full Text] [Related]
16. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
Komatsu-Fujii T; Ogawa M; Nonoyama S; Fukumoto T; Tanabe H
Eur J Dermatol; 2021 Feb; 31(1):98-99. PubMed ID: 33586655
[No Abstract] [Full Text] [Related]
18. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
Lee O; Masood M; Nutan F
J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
[TBL] [Abstract][Full Text] [Related]
19. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
Shah KM; Rancour EA; Al-Omari A; Rahnama-Moghadam S
Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142712
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]